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Early-onset of colorectal cancer (EOCRC) is increasing amongst younger populations. A 
main contributing factor is modern-day diets. Clinical studies indicate that high fibre nutrition 
regimens may be protective against the EOCRC. An abundant metabolite of fibre is butyrate, 
which has been observed to mitigate the loss of intestinal mucus and E-cadherin in human 
colorectal adenocarcinoma cell lines. E-cadherin facilitates intercellular signalling, which is 
essential for the suppression of tumorigenesis and metastasis progression. Bacteroides 
fragilis toxin (BFT) is a metalloprotease virulence factor of enterotoxigenic B. fragilis 
(ETBF) that induces the cleavage and degradation of E-cadherin. ETBF is commonly found 
colonised in the intestinal mucus of patients who were susceptible to developing colorectal 
neoplasia and pre-cancerous lesions. Associations between butyrate’s potential level of 
protection against BFT is yet to be explored in current literature. Thus, in this study, ETBF 
was used as a bacterial model to test the hypothesis that butyrate acts to upregulate E-
cadherin and/or mucus production, which protects against B. fragilis-mediated cellular 
responses in colonic adenocarcinoma cells. 
 
The cellular effects of butyrate are conventionally investigated in the undifferentiated HT29 
cell line. However, the mucus secreting HT29-MTX cells are postulated to be more 
physiologically representative of the colonic epithelia. Both HT29 and HT29-MTX cell lines 
were used to model BFT-mediated loss of E-cadherin. These cells were treated with 5 mM of 
butyrate and/or B. fragilis for 24-hours. Trypan blue exclusion was applied to quantify cell 
proliferation and viability. RT-qPCR was utilized to quantify CDH1 and MUC2 gene 
expression, which encodes for E-cadherin and mucin 2 (intestinal mucus) respectively. 
Alcian blue staining was implemented to assess acidic mucin expression. Immunofluorescent 




Findings of this study indicated 2-8 mM of butyrate had no significant effect on B. fragilis 
growth or viability. In uninfected HT29 cells, butyrate increased CDH1 (3.30-fold, P<0.05) 
and plasma membrane-associated E-cadherin expression. This effect was not concentration 
dependent. Butyrate (5 mM) also increased CDH1 (1.99-fold, P<0.01) and E-cadherin protein 
levels in ETBF-infected HT29 cells. Similarly, butyrate increased CDH1 expression in 
uninfected (7.32-fold, P<0.01) and infected (6.11-fold, P<0.05) HT29-MTX cells. Butyrate 
also upregulated acidic mucin expression in mucin granulae and reduced MUC2 expression. 
Further investigation is needed to determine the effect of butyrate on E-cadherin and mucin 2 
protein expression in HT29-MTX cells. This study provides insight into further investigation 
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1.1 Colorectal cancer  
Colorectal cancer (CRC) derives from irregularly aggregated cells in the intestinal mucosa 
that form premalignant, benign polyps. Given time, some polyps acquire malignant 
characteristics, progressing to cancer (1).  
 
CRC is the third and second most diagnosed cancer worldwide in men and women, 
respectively (2). In 2018, CRC was recorded as the second most common cause of cancer-
related mortality in New Zealand (3). In comparison with worldwide cases, Australia and 
New Zealand have the highest age-standardised incident rates (32.3 and 44.8 per 100,000 
women and men, respectively) (4). Although at present individuals over 50-years old are 
more likely to be diagnosed with CRC, this trend is predicted to shift towards a higher 
incidence rate amongst younger individuals between the ages of 20 and 34 years old by 2030 
(5). Only 35% of cases among younger populations are currently found to be associated with 
hereditary factors (6). This suggests that the remaining 65% of cases may be sporadic onset 
CRCs attributed by environmental and lifestyle factors. 
 
1.2 Dietary risk factors 
A major lifestyle factor that influences the aetiology of CRC is dietary intake. Western-styled 
diets are associated with an increased risk of developing CRC, whereas a prudent-style diet is 
found to be protective (7-9). Western diets are defined by a high consumption of 
red/processed meats, refined grains, sugar, and low consumption of vegetables/fruits. In 
contrast, a prudent diet consists predominantly of fruits/vegetables and notably less red and 
processed meat (7, 9). The western-styled dietary pattern correlates with rise in urbanisation 




more processed foods (10). This concept fits well with the increase in sporadic CRC seen 
amongst younger populations in New Zealand and around the world (10, 11). 
 
1.3 Dietary fibre 
Both human and animal food intervention studies have suggested the importance of dietary 
fibre intake, particularly as a modifiable risk factor in the prevention of CRC. Increasing fibre 
consumption from 15.4 to 30.6 g per day is associated with a 27% reduction in adenoma risk 
(12). This risk attenuation is dependent on the type of fibre consumed (12, 13). Dietary fibre 
can be found in several food groups including cereals, fruits, vegetables, nuts, seeds and 
legumes and consists of soluble and insoluble fibre (14). Soluble fibre is fermented by gut 
bacteria into metabolites such as short-chain fatty acids (SCFA), whereas insoluble fibre is 
less rapidly metabolised and instead contributes to the bulking of stools (14). 
 
1.4 Gut Microbiota and the production of dietary metabolites 
More recently, the gut microbiome has also been implicated as another variable that 
influences the aetiology of CRC (15, 16). An infant begins to develop a unique gut microbial 
population, acquired during parturition, that is fully established by the age of three (17). An 
individual’s microbiota typically remains consistent throughout their life, with some 
exceptions, such as pregnancy and living past the age of 65, in which the diversity and 
abundance of selective bacteria are increased (17). In healthy individuals, the symbiotic 
relationship between these microorganisms and their host maintains gut homeostasis (18). 
However, when this balance is perturbed (also known as dysbiosis), subsequent changes in 
the gut environment are thought to contribute to the onset of inflammatory associated 




Gut bacteria, like their human hosts, require food to survive and diet is known to heavily 
influence the luminal environment and hence the relative abundance of bacteria present in the 
colon at any time (21). European western-styled diets low in fibre, high in sugar, saturated 
fats and proteins are associated with reduced microbial biodiversity and a lower ratio of 
Bacteroidetes:Firmicutes when compared to African diets high in plant fibre and low in 
animal fats and proteins. This suggests that geographically-associated dietary patterns can 
alter the gut microbial profile, which may influence disease risk, including CRC. 
 
There is growing evidence to suggest that a fibre-rich diet is associated with the upregulation 
of prebiotic bacteria and their derived metabolites that are beneficial for gut health. These 
metabolites include acetate, propionate and butyrate (22). Populations consuming a diet rich 
in fibre were initially found to be colonised with an increased relative abundance of butyrate-
producing bacteria. That, in turn, was associated with increased butyrate production. 
However, when switched to a low-fibre diet, the relative abundance of the butyrate-producing 
bacteria was reduced (9). This is exemplified by clinical studies that detect a reduction in the 
abundance of butyrate-producing bacteria in faecal samples of individuals diagnosed with 
CRC (20, 23, 24).  
 
Moreover, when dietary fibre is limited, colonic bacteria can begin to degrade host-derived 
mucus-associated proteins, resulting in the production of metabolites that are associated with 
increased risk of cellular DNA damage (25). Mouse studies have shown that dysbiosis 
correlates with polyposis when SCFA-producing bacteria are absent. However, following the 
initiation of a high-fibre diet and the reintroduction of SCFA-producing bacteria, SCFA 




animals (26). This suggests that fibre possess prebiotic effects that may attenuate the 
development of CRC. 
 
1.5 Butyrate  
Butyrate, also known as butyric acid, is a 4-carbon weak organic acid that is synthesised from 
the fermentation of complex carbohydrates (dietary fibre) by anaerobic bacteria residing in 
the colon (14, 27). In the colon, butyrate is present at 1-10 mM at physiological 
concentrations (28, 29). In mouse models, butyrate is shown to be protective against CRC in 
a dose-dependent manner (30).There are several beneficial functions of butyrate at the 
intestinal and cellular level. This includes its role as an energy source to fuel colonocytes and 
its ability to regulate proto-oncogenes to maintain mucosal health and gut barrier function 
(31-33).  
 
Whereas butyrate is considered the preferred primary fuel source for colonocytes, high 
butyrate concentrations reportedly starve colorectal adenocarcinoma cells, driving apoptosis 
(32). Moreover, during pre-colorectal carcinogenesis, expression of the butyrate receptor on 
colonocytes is downregulated (34). This may indicate a switch of colonocyte fuel source 
away from butyrate, further supporting the role of butyrate in preventing malignancy in early 
stages of CRC (34). Furthermore, butyrate is a histone deacetylase inhibitor that promotes 
histone acetylation, enabling proto-oncogene regulation (31). This is the overarching 
mechanism in which butyrate facilitates anti-carcinogenic cellular processes involved in 
proliferation, polarisation and inflammation (31, 33). Collectively, these characteristics 
indicate that butyrate is protective against CRC and these features may explain the 




1.5.1 Butyrate and intestinal mucus 
Intestinal mucus is constantly secreted by the mucus secreting goblet cells and contributes to 
intestinal barrier function by protecting the mucosa from mechanical and chemical stresses in 
the lumen (35, 36). The lubricant properties of mucus maintain the structural integrity of 
colonic epithelium when dietary contents pass through the lumen (37). Mucus acts as a 
semipermeable layer, which allows the exchange of essential molecules such as nutrients, 
whilst limiting the number of pathogens and bacteria interacting with the surface epithelium 
(37). 
 
The component of mucus that is responsible for its gel-like consistency is mucin (38). Mucins 
are synthesised in the endoplasmic reticulum where they are transported to the golgi complex 
and packed into secretory granulae (39). As these granulae mature, they become capable of 
occupying >75% of the cytoplasmic volume (40). These granulae then fuse to the plasma 
membrane to renew the mucus layer on mucosal surface (41). There are several classes of 
mucins that are secreted by goblet cells, each are characterised by their various amino acid 
residues at the mucin domain (38). All mucins are extremely O-glycosylated, thus enabling a 
rigid structure when mucins polymerise (38, 42). The most abundant class of secreted 
intestinal mucin is mucin 2, which forms the majority of the mucus layer (38, 43).  
 
The mucus layer is divided into two layers in the colon, a thicker outer layer housing 
commensal bacterium and an inner layer that restricts bacterial interactions and adheres to the 
surface epithelium (38, 44). From the proximal to distal colon, as the outer mucus layer 
thickness increases, so does the bacterial density capacity (Figure 1.1) (42, 45). However, in 
the absence of dietary polysaccharides, such as fibre, mucus glycans can be degraded by 




thickness and increase the permeability of the mucus layer, increasing the risk of exposing 
the epithelial barrier to potential harm (48). 
 
  
Figure 1.1: The mucus layer thickness along the large bowel. The overall mucus layer 
thickness increases from the proximal to the distal end of the human bowel. This increase is 
most prevalent in the outer mucus layer. Figure from Barnett et al. (42). 
 
 
MUC2-knockout mice are more prone to developing CRC (43, 49). In these mice, the overall 
thickness of the mucus layer thickness is diminished, enabling potentially toxigenic bacteria 
and luminal contents to interact with the epithelium (49). This directly subjects the 
colonocytes to mechanical and chemical stresses that induce unfavourable cellular 
morphological changes such as a reduction in cellular differentiation, atypical crypt 
morphology, the presence of colonic lesions and overall reduced structural integrity (36, 43, 
49). Moreover, reduced cellular differentiation is associated with the absence of goblet cell 
maturation, further impairing mucus secretion (43). These alterations contribute to the 
progression of inflammation, proliferation, and colitis (49). 
 
Additionally, butyrate-producing bacteria in the presence of fibre polysaccharides are shown 
to prevent the deterioration of the mucus layer (48). This observation is further supported by 




a reduced abundance of butyrate-producing bacteria and an increased abundance of mucus-
degrading bacteria (23). Collectively these findings support an association between the lack 
of butyrate and reduced colonic mucus to an increased risk of CRC. 
Previous cell culture studies have observed that lower concentrations of butyrate treatment 
(<5 mM) are associated with increased mucin 2 expression and gene transcription (50-52). 
However, there is no consensus about whether 5 mM of butyrate induces an increase, 
decrease or unchanged gene and protein expression of mucin 2 (51, 53, 54). These 
contradictory results may reflect the use of different human colorectal cancer cell lines and/or 
differing experimental designs (e.g. treatment length, growth conditions, culture media and 
differentiation-inducing substrates). 
 
1.5.2 Butyrate and E-cadherin 
E-cadherins are highly specific and abundant calcium-dependent cell adhesion molecules that 
facilitate adjacent cell interactions. Intercellular signalling is essential for the suppression of 
proliferation and normal cell differentiation (55). The downregulation of the CDH1 gene (that 
encodes E-cadherin) in cancer cells results in the loss of contact-induced inhibition and 
increased cell locomotion, which correlates with tumorigenesis and metastasis (55). Thus, 
CDH1 is considered to be a tumour suppressor gene (55). E-cadherins are essential for 
maintaining intestinal epithelial cell morphology, tissue formation, and overall cellular 
homeostasis (56, 57). 
 
The mature 120 kDa isoform of E-cadherin consists of an extracellular, cytoplasmic and 
transmembrane domain. The extracellular domain contains five tandem repeats and calcium 
binding sites that interact with E-cadherins on adjacent cells. The cytoplasmic (intracellular) 




juxtamembrane domain is essential for catenin aggregation which promotes the strength of 
adhesion via p120-catenin. The catenin-binding domain in turn facilitates binding of the actin 
cytoskeleton to β-catenin via the linkage of α-catenin. (Figure 1.2) (58). 
 
 
Figure 1.2: E-cadherin structure mediates adjacent cell junction formation. The 
extracellular domain of adjacent cells binds together to form the adherens junction. The 
intracellular domain contains the juxtamembrane domain and the catenin-binding domain, 
which are essential for catenin aggregation and catenin binding for actin cytoskeleton linkage. 
Figure from Gall et al. 2013 (58). 
 
Previous studies using HT29 colonic epithelial cells show that butyrate can upregulate E-
cadherin transcription, intracellular localisation and isoform expression in these cells (59, 60). 
Microarray analysis that demonstrates butyrate-mediated upregulation of CDH1 support these 
findings (31). Reduced CDH1 gene expression correlates with the increased invasiveness of 
tumours, poorer disease-free survival among individuals with CRC and the loss of cellular 
differentiation in colorectal adenoma cells in vivo and in vitro (58, 61, 62). Thus, the 
butyrate-mediated increase in CDH1 may potentially help maintain epithelial homeostasis by 





1.6 A bacterial model of colon carcinogenesis 
The bacterial-driven passenger colorectal carcinogenesis model proposed by Tjalsma et al. 
(63) describes how gut bacteria may facilitate the development of colorectal carcinogenesis. 
Initially, driver-bacteria invoke pre-carcinogenic changes such as cell proliferation, 
inflammation, colonic lesions or proto-oncogenic metabolites. The characteristics invoked by 
these bacteria may be enhanced by diet, further modifying the microbial environment of the 
lumen. This altered environment promotes the habitation of passenger-bacteria that may 
outcompete the original driver-bacteria. Passenger-bacteria are either pathogenic or 
commensal microorganisms that progress or suppress tumorigenesis (63). Examples of 
potential passenger and driver bacteria in the colon are butyrate-producing bacteria and 
enterotoxigenic Bacteroides fragilis, respectively (63, 64). 
 
1.6.1 Bacteroides fragilis 
Bacteroides are a genus of anaerobic, non-spore forming, gram negative bacteria that are part 
of the healthy human intestinal microflora (65). These symbiont bacteria are essential for host 
nutrition and mucosal immunity (66). B. fragilis, one of 20+ subspecies of Bacteroides, exists 
as two strains, non-toxigenic B. fragilis (NTBF) and enterotoxigenic B. fragilis (ETBF) (65). 
ETBF is known to produce only one virulence factor - B. fragilis toxin (BFT). BFT is a 20 
kDa zinc-dependent metalloprotease toxin of the metzincin superfamily (65). Of the three 
known isoforms encoded by the bft1, bft2 and bft3 genes, bft2 exhibits the greatest biological 
activity of the three, followed by bft1 and bft3 respectively (67, 68). 
 
Clinical studies have observed that elevated ETBF colonisation correlates with the incidence 
of colorectal neoplasia and an increased risk of pre-cancerous lesions (64, 65, 69). ETBF is 




controls (70, 71). Additionally, mice colonised with ETBF are more prone to developing 
hyperplasia, colitis and pre-cancerous characteristics (72). Collectively, these studies 
emphasize the physiological relevance of using ETBF as a bacterial model of colon 
carcinogenesis. 
 
1.6.2 BFT-mediated cleavage of E-cadherin 
BFT induces the cleavage and degradation of its substrate E-cadherin in HT29 cells (73). 
BFT-mediated cleavage of E-cadherin is facilitated by the activation of the G protein-coupled 
receptor (GRP) 35 (69). This triggers several intracellular signal transduction cascades 
leading to the cleavage of E-cadherin and subsequent degradation, further enhancing colonic 
epithelial cell proliferation (Wnt-signalling), permeability, inflammation, and DNA damage 
(Figure 1.3) (67). 
 
Figure 1.3: A summary of the known cellular actions of BFT. BFT binds to the GRP35 
receptor on colonic epithelial cells, inducing several intracellular signal transduction cascades 
leading to the cleavage of E-cadherin, cell proliferation, permeability, inflammation, and DNA 




In conjunction with these downstream effects, deteriorated morphology promotes the 
development of tumours (74). These findings suggest that ETBF could be an early 
interventional target to reduce the detrimental downstream effects of E-cadherin cleavage that 
progresses into colorectal carcinogenesis. Therefore, ETBF’s association with E-cadherin 
may be used as a bacterial model to test the upregulation of the adhesion proteins and the 
preventative effects of butyrate on colon carcinogenesis. 
 
1.6.3 ETBF-mediated effects on mucus 
B. fragilis is known to abundantly colonise the outer intestinal mucus layer and is one of few 
tightly regulated bacterial species that are present in the inner layer and crypts (45). B. 
fragilis binds to highly purified mucins in vitro, suggesting that the bacteria likely adhere to 
the colonic mucus layer by binding to intestinal mucins (75). 
Dejea et al. (76) observed a reduction in mucus thickness in HT29-MTX cells colonised with 
ETBF. This was reportedly associated with DNA damage of the cells, increased mucosal 
habitation of the pathogenic bacteria and a more rapid onset of tumorigenesis (76). 
Furthermore, a reduced expression of MUC2 gene expression was observed when intestinal 
neoplastic mice were treated with BFT2 for 24 hrs. However, this alteration in MUC2 
expression only persisted when BFT treatment was continuous (77). This suggests that the 
ETBF-mediated decrease of mucus thickness is reversible. 
 
1.7 Research rationale and objectives 
Previous literature has emphasised the beneficial role of butyrate in CRC prevention. 
However, there is limited information about butyrate’s effect on E-cadherin cleavage and 
mucus production in more physiologically relevant mucus-producing cell lines. Presently, no 




Therefore, based on the literature, the overarching hypothesis of this project was that butyrate 
acts to increase E-cadherin expression and/or mucus production, which protects against BFT-
mediated E-cadherin loss that, in turn, helps maintain epithelial homeostasis in the gut. Using 
HT29 and HT29-MTX cells colonised with ETBF as a bacterial model for loss of E-cadherin 
and/or mucus, the aim of this study was to understand the mechanism(s) of action behind the 
potential protective effects of butyrate in regard to CRC.  
 
To accomplish this, the following objectives were established:  
1) Establish an optimal seeding concentration of HT29 cells to yield ~80% confluency 
48 hours post seeding.  
2) Establish an optimal concentration of ETBF (multiplicity of infection) that yields 
~50% of HT29 cell rounding following 24 hours of infection. 
3) Establish a minimum concentration of butyrate that does not significantly impact 
HT29 cell and/or B. fragilis growth and viability over a 24-hour period. 
4) Investigate the effect that butyrate has on HT29 cells with and without the addition of 
B. fragilis. 
5) Establish the effect that treatment with 5 mM of butyrate has on E-cadherin and 
mucus expression in HT29-MTX cells over time. 
6) Investigate E-cadherin and mucus expression in HT29-MTX cells with and without 
the addition of butyrate and B. fragilis.  
 
It is envisaged that the results gained from this project will provide insight into better 
understanding the relationship between how dietary metabolites might act to protect the colon 
from pre-cancerous changes, which are increasingly understood to be driven by certain 




ETBF toxin-mediated changes in epithelial cells could lead to the further investigation of 
butyrate as a potential chemo-preventative therapy against BFT-mediated colorectal 






2 Materials and methods 
2.1 HT29 cells 
2.1.1 Maintenance 
HT29 (The American Type Culture Collection, HTB-398) cells are human colorectal 
adenocarcinoma cells that can be used to model the colonic epithelium in vitro. Cells were 
grown in 25 cm2 culture flasks (Corning Incorporated, New York, USA) in McCoy’s 5A 
growth medium (Gibco, Auckland, New Zealand), supplemented with 10% Hyclone Fetal 
Bovine Serum (FBS) (Gibco) and 1% penicillin-streptomycin (Gibco). The cells were 
incubated in 95% air, 5% CO2 at 37oC and were passaged twice a week. Dulbecco’s 
Phosphate Buffered Saline (DPBS) (Gibco) was first used to wash the cells (to remove any 
remaining serum that may inhibit trypsin) before the addition of 1 mL of TrypLE Express 
(Gibco) for 10 min at 37◦C to dissolve adherence proteins which maintain cell association 
with the surface of the flask. TrypLE activity was then neutralised by the addition of 9 mL of 
growth medium to the flask. To subculture the cell line, 1 mL of this suspension was added to 
9 mL of growth media in a new flask, resulting in a 1:10 splitting ratio. 
 
2.1.2 Culture 
All HT29 cell experiments were seeded at a concentration of 5x104 cells/mL (in 1 mL or 200 
µL of McCoy’s 5A growth medium for 24-well and 96-well plates, respectively) and grown 
for an initial 48 hours to enable the cells to adhere to the cell culture plate wells prior to 
treatment. Culturing HT29 cells in growth media containing 10% FBS is standard practice. 
However, this percentage is known to mitigate the toxigenic activity of the B. fragilis toxin 
(BFT) (78). Hence, in subsequent experiments involving HT29 cells treated with BFT-




containing 1% FBS. Penicillin and streptomycin were also removed from this media as they 
reduce bacterial viability. 
 
2.2 HT29-MTX cells 
2.2.1 Maintenance  
HT29-MTX-E12 (The European Collection of Cell Cultures, 12040401) cells are HT29 cells 
that have been differentiated into almost exclusively mucus secreting cells by methotrexate 
treatment (79). Passage of these cells was similar to that of HT29 cells but in a different 
growth medium (Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) supplemented with 
10% Hyclone FBS, 1% penicillin-streptomycin and 1% MEM non-essential amino acids 
(Gibco)) (52, 77). The trypsinised cell suspension was diluted in 2:5 in media when sub-
culturing a new flask. The growth rate of these cells is slower than HT29 cells. Hence, a 
lower dilution ensured an ideal confluency to passage every 2-3 days. 
 
2.2.2 Culture 
All HT29-MTX cell experiments were seeded at a concentration of 5x104 cells/mL (in 1 mL 
or 200 µL of DMEM growth medium for 24-well and 96-well plates, respectively) 24 hours 
prior to further culture with and without the addition of 5 mM of butyrate for up to 10 days. 
DMEM growth medium was replaced every 2-3 days. As stated above (Section 2.1.2), the 
cell culture media was replaced with growth medium containing 1% FBS for experiments 





2.3 Cell proliferation and viability 
2.3.1 Cell collection 
Firstly, the supernatant from individual wells was collected (to accurately represent the 
number of non-viable cells not adhering to the monolayer). Each remaining cell monolayer 
was then washed three times in 500 µL of DPBS, with each wash added to the respective 
supernatant. TrypLE (500 µL) was added to each well and the plate was incubated at 37oC for 
10 minutes. The trypsinised cells were then added to the respective supernatants and DPBS 
washes (a total of 3.5 mL for each well). To concentrate the cell suspensions (5-fold), 1 mL 
was centrifuged (1,300 x g for 5 minutes) and resuspended in 200 µL of growth media. 
 
2.3.2 Cell proliferation. 
To enumerate the cells, the cell suspension was added in a 1:1 ratio to 0.5% (w/v) Trypan 
blue (Sigma-Aldrich, Auckland, New Zealand) in DPBS and counted on a haemocytometer 
under a microscope. The number of cells in the 4x4 grids of each of the corners were counted 
and considered as four technical repeats. The repeats were averaged, corrected for the trypan 
blue dilution (multiplied by 2), the 5-fold concentration (divided by 5), the total volume 
(multiplied by 3.5) and multiplied by 104 to give the concentration of cells/mL. 
 
2.3.3 Cell viability 
Non-viable cells are readily stained by Trypan blue stain, thus Trypan blue exclusion can be 
used to determine the number of viable and non-viable cells in a suspension (80). The 
percentage of non-viable cells was calculated by dividing the number of non-viable cells with 





2.4 Butyrate stock solutions 
A stock solution of butyrate (0.5 M) was prepared by dissolving 55mg of sodium butyrate 
(Sigma-Aldrich) in 1 mL of DPBS. The solution was sterilised through a 0.2 µm syringe filter 
(In Vitro Technologies, Auckland, New Zealand). Aliquots were stored at -80oC degrees and 
thawed when needed.  
 
2.5 CDH1 and MUC2 gene expression  
Cells were grown in 24-well plates (Nunc, Auckland, New Zealand) prior to treatments. For 
analysis of gene expression, the supernatant was removed from individual wells and the 
remaining cell monolayer was washed once (500 µL of DPBS) before the addition of 350 µL 
of RNA lysis buffer (Qiagen, Venlo, Netherlands). The resultant cell homogenates were 
collected into sterile tubes and stored at -80oC prior to RNA extraction. 
 
2.5.1 Real time quantitative polymerase chain reaction (RT-qPCR) 
RNA extracted using the RNeasy Mini Kit quick-start protocol (Qiagen) was eluted into 40 
µL of RNase-free water (Qiagen) and quantified using a Nanodrop spectrophotometer 
(ThermoFisher, Auckland, New Zealand). Precaution was taken to keep thawed samples on 
ice at all times to prevent RNA degradation. Complementary cDNA was prepared by adding 
1µg of RNA to 4 µL of Qscript XLT cDNA Supermix (Quantabio, Massachusetts, USA). 
RNase-free water (Qiagen) was added to the mixture to a combined total of 20 µL. A 
Supercycler (Kyratec, Queensland, Australia) was used to facilitate reverse transcription 
(25oC for 5 minutes, 45oC for 1 hour and 85oC for 5 minutes). The samples were stored at      





CDH1 (encodes for E-cadherin) and MUC2 (encodes for mucin 2) gene expression was 
quantified by RT-qPCR. HPRT (encodes for Hypoxanthine-guanine-
phosphoribosyltransferase) was utilised as the housekeeping gene. Each sample reaction was 
performed in three technical repeats and was composed of 3.5 µL/well of RNase free water, 5 
µL/well of SYBR green (Invitrogen, Auckland, New Zealand), 0.25 µL/well of both gene 
specific reverse and forward primers (Table 1) and 1 µL of cDNA. These samples were 
processed using a Lightcycler 480 (Roche, Basel, Switzerland) for 45 cycles at 58oC, 70oC 
and 95oC for 15, 10 and 5 seconds respectively. The melt peaks and amplification curves of 
the samples were analysed to ensure specificity and purity. The CP (crossing point) values 
generated were used to quantify CDH1 gene expression ratios. 
Table 1. RT-qPCR primers and sequences 
Target Primer Sequence (5’-3’)  Reference 
CDH1 Forward TGCCCAGAAAATGAAAAAGG (81) 
 Reverse GTGTATGTGGCAATGCGTTC  
MUC2 Forward AAGACGGCACCTACCTCG (82) 
 Reverse TTGGAGGAATAAACTGGAGAACC  
HPRT Forward TGACCTTGATTTATTTTGCATACC (83) 
 Reverse CGAGCAAGACGTTCAGTCCT  
 
 
2.6 Bacteroides. fragilis  
2.6.1 Culture and quantification 
The enterotoxigenic B. fragilis (ETBF) strain 86-5443-2-2 and non-toxigenic B. fragilis 
(NTBF) strain NCTC9343 used in this study were kindly donated by Professor Cynthia Sears 
(John Hopkins University, Baltimore). ETBF strain 86-5443-2-2 is recognized to produce 
BFT2 toxin subtype (84). The NTBF strain was used as a negative control for BFT. The 




Auckland, New Zealand) at 37oC under anaerobic conditions obtained using anaerobic 
sachets (Mitsubishi Gas Chemical Company, Tokyo, Japan). Each strain was sub-cultured 
twice a week from a single colony.  
 
To quantify B. fragilis prior to treatment of cultured cells, bacteria were harvested into 1 mL 
of sterile Phosphate Buffer Saline (PBS) (140 mM NaCl, 2.6 mM KCl, 8.2 mM Na2HPO4 
w/v, pH 7.4), washed three times (10,000 x g for 5 minutes) and resuspended in fresh sterile 
PBS. Five- and ten-times dilutions were made (in sterile PBS) and the absorbance of 100 µL 
aliquots of each dilution was measured at a wavelength of 600nm using a Multiskan FC 
Microplate photometer (ThermoFisher). The concentration of B. fragilis was estimated on the 
basis of a standard curve, where an absorbance of 0.1 (A600nm) was determined to be 
approximately equivalent to 1x108 bacteria/mL after taking the dilutions into account. 
 
2.6.2 B. fragilis growth  
ETBF or NTBF (1x108/mL) were cultured in 100 µL volumes of sterile B. fragilis growth 
media (3.2% Brian Heart infusion (Oxoid, Hampshire, UK), 0.5% yeast extract (Merck, 
Auckland, New Zealand), 0.2% Hemin (Sigma-Aldrich), 0.01% L-cysteine (Sigma-Aldrich), 
0.004% vitamin K (Sigma-Aldrich)) in flat-bottom 96-well plates (Corning Incorporated) 
with and without the addition of butyrate. The absorbance of each well was measured at 0 
hours and again after 24 hours of anaerobic incubation (37oC, gentle agitation) using a 
Multiskan FC Microphotometer (as detailed in Section 2.6.1). Each sample was measured 
across eight technical replicates, with results averaged and corrected for the absorbance of the 
cultured media by the subtraction of the non-infected control wells (four technical replicates). 





2.6.3 B. fragilis viability 
To determine the number of viable bacteria in each sample, the eight technical repeats of the 
butyrate treated infected wells were collected and diluted in PBS to a standardised 
concentration of 1x108 bacteria/mL. The samples were further diluted in PBS in a 
1/10,000,000 manner. These dilutions were inoculated onto Sheep Blood Agar plates (in 
three technical repeats) and incubated for 48 hours (37oC, anaerobic conditions). Colony 
forming units (CFUs) were enumerated, adjusted for dilutions, and used to calculate the 
number of viable bacteria in each sample. 
 
2.7 Toxigenic activity of B. fragilis on cell morphology  
BFT-mediated cleavage of E-cadherin in HT29 cells is shown to be associated with the 
occurrence of cell rounding (73). To visualise this morphological change, ETBF and/or 
butyrate treated HT29 cells were imaged using a 1X81 bright-field microscope (Olympus, 
Tokyo, Japan) with the CellSens Dimension software (version 1.16, 2016, Olympus) at 20x 
magnification.  
 
2.8 Immunofluorescent microscopy 
The supernatant of each well was discarded and the cells were fixed in 100 µL/well of 1:1 
methanol (LabServ, Auckland, New Zealand) and acetone (Sigma-Aldrich) for 20 minutes. 
This was followed by three 5-minute washes in 200 µL of PBS-T (DPBS-0.1% Triton X-100 
(Sigma-Aldrich). To visualise E-cadherin, the primary antibody (ab76055, mouse-derived 
monoclonal IgG to E-cadherin (Abcam, Melbourne, Australia)) was prepared as a 1:200 
dilution in immunobuffer (1% Bovine serum albumin (Gibco) in PBS-T) and applied (100 
µL/well) overnight (4oC, gentle agitation). The next day, the unbound primary antibody was 




minutes. The Alexa Fluor-labelled secondary antibody used to visualise E-cadherin and 
mucin 2 was ab150120 (goat-derived polyclonal mouse IgG conjugated to Texas Red 
(Abcam, Melbourne, Australia)) and ab6804 (sheep-derived polyclonal mouse IgG 
conjugated to FITC (Abcam), respectively. These antibodies were diluted 1:1000 (ab150120) 
and 1:500 (ab6804) in immunobuffer and Hoechst 33342 (Invitrogen) (2.5ug/mL). Aliquots 
of 100 µL/well were applied for 2-4 hours in the dark. The wells were washed two times in 
PBS-T and imaged in 100 µL PBS using the ImageXpress® Pico Automated Cell Imaging 
System (Molecular Devices, California, USA). Each treatment (in duplicate) was imaged 12 
times per well across five transverse focus planes to ensure that the images were 
representative of the samples. The images were further processed using ImageJ software 
(version 1.53k, National Institutes of Health, Maryland, USA) to visualise the fluorescence of 
each channel.  
 
2.9 Alcian Blue staining  
HT29-MTX cells are characterised by the production of mucus (79). Alcian blue dye, which 
possesses cationic properties at a pH of 2.5 allowing the dye to bind to the anionic 
carboxylated sulphated polysaccharide chains of mucins, is used to visualise mucus 
production by these cells (85). 
 
HT29-MTX cell monolayers grown on ethanol sterilised glass coverslips (Paul Marienfeld 
GmbH, Lauda-Konigshofen, Germany) were gently washed three times in 500 µL of DPBS 
before being fixed in Methanolic Carnoy’s fixative (60% methanol, 30% chloroform (Sigma-
Aldrich), 10% glacial acetic acid (Merck, Auckland, New Zealand) for 4 hours. The 
coverslips were rinsed several times in distilled water and stained with 1% Alcian blue 




minutes before being rinsed again in distilled water. The cell nuclei were counterstained with 
haematoxylin solution for 90 seconds. The coverslips were rinsed in distilled water, air-dried, 
inverted onto 40% glycerol (Fisher Scientific, Loughborough, UK) on glass slides and 
imaged using a Zeiss Axio Imager Z1 microscope (Auckland, New Zealand). 
 
2.10 Statistical analysis 
For experiments where individual treatments were tested in technical replicates, the mean 
result was generated using Excel (Microsoft, 2016). The mean results from three independent 
experiments were then analysed on Prism (GraphPad Software Incorporated, Version 9.1.1, 
California, USA) to determine statistical significance and standard error of the means. To 
analyse cell proliferation, viability and B. fragilis growth and viability, Dunnett's multiple 
comparisons test was used to perform an Ordinary one-way analysis of variance (ANOVA). 
Analysis of gene expression in uninfected cells was performed on non-normalised data using 
repeated measures of ANOVA in combination with Holm-Sidak’s post hoc test. Statistical 
analysis of gene expression in B. fragilis infected cells was likewise performed on non-
normalised data, in this instance using repeated measures of ANOVA in combination with 





3 Results: HT29 cells 
Background 
Human colorectal adenocarcinoma HT29 cell lines grown in the presence of glucose exhibit 
an undifferentiated phenotype, representing cells at the base of the colonic crypt (86, 87). 
Previous literature has conventionally used HT29 cells to model epithelial cell responses in 
vitro to ETBF pathogenesis (57, 73, 74, 88-90). In these studies, the B. fragilis toxin (BFT)-
associated cell rounding of HT29 cells is used as a morphological indicator of E-cadherin 
protein cleavage (73).  
Butyrate is known to upregulate E-cadherin protein and CDH1 (gene that encodes E-
cadherin) expression in HT29 cells (31, 59, 60). However, the literature is yet to investigate 
whether butyrate can mitigate BFT-mediated E-cadherin gene or protein loss. In this chapter, 






7) Establish an optimal seeding concentration of HT29 cells to yield ~80% confluency 48 
hours post seeding.  
8) Establish an optimal concentration of ETBF (multiplicity of infection) that yields ~50% 
of HT29 cell rounding following 24 hours of infection. 
9) Establish a minimum concentration of butyrate that does not significantly impact HT29 
cell and/or B. fragilis growth and viability over a 24-hour period. 





3.1 Optimising Seeding Cell Density  
HT29 cells are conventionally grown to approximately 80% confluency prior to exposure to 
the B. fragilis toxin (88). To optimise the seeding cells density required to achieve a similar 
level of confluency, HT29 cells were seeded at three different concentrations (1x104, 5x104 
and 1x105 cells/mL suspended in 1 mL of McCoy’s 5A growth medium) and grown for 48 
hours in a 24-well plate prior to being imaged. Seeding at 1x104 cells/mL resulted in too few 
cells (~10%) whereas 1x105 cells/mL neared 100% confluency after 48 hours growth (Figure 
3.1A, 3.1C). In contrast, cells seeded at 5x104 cells/mL appeared to be ~80% confluent 
(Figure 3.1B). This seeding cell density was selected for subsequent experiments. 
  
Figure 3.1: HT29 cell densities following 48 hours of growth. Cells were seeded at a 
concentration of (A) 1x104, (B) 5x104 or (C) 1x105 cells/mL. Bright-field microscopy was used 




3.2 Determining the multiplicity of infection (MOI) of ETBF  
HT29 cells (5x104 cells/mL suspended in 1 mL of McCoy’s 5A growth medium) were grown 
for 48 hours in a 24-well plate. At this time point, the cells have doubled twice (once every 
24 hours) to a concentration of ~2x105cells/well. The cells were treated with or without B. 
fragilis diluted in fresh media containing 1% FBS for a further 24 hours. Enterotoxigenic B. 
fragilis were added at multiplicities of infection (MOI) ranging from 10:1 to 500:1 bacterium 
per cell (equivalent to 2x106 to 1x108 bacteria/mL). As the MOI increased, cell rounding was 




(Figure 3.2). For a BFT-negative control comparison, nontoxigenic B. fragilis (NTBF) were 
added at a MOI of 500:1. HT29 cells treated with NTBF MOI 500:1 did not appear to differ 
morphologically from the untreated cells (Figure 3.2B). In contrast ETBF added at a MOI 
500:1 resulted in ~50% of the HT29 cells rounding (Figure 3.2F). This MOI was selected for 
subsequent experiments. 
 
Figure 3.2: HT29 cell rounding in response to increasing multiplicity of infection (MOI) 
with ETBF. The cells were either (A) untreated, (B) treated with NTBF (MOI 500:1), or treated 
with ETBF at (C) MOI 10:1, (D) MOI 100:1, (E) MOI 300:1 or (F) MOI 500:1 for 24 hours 
before being imaged. Bright-field microscopy was used to image cells at 10x magnification. 




3.3 The effect of butyrate on HT29 cell proliferation and viability 
HT29 cells (5x104 cells/mL suspended in 1 mL of McCoy’s 5A growth medium) were grown 
for 48 hours in 24-well plates prior to the addition of butyrate (0-8 mM) for a further 24 
hours. Cell counts indicated that the growth of butyrate-treated cells was not different from 
that of untreated cells (P>0.05, Figure 3.3A). Likewise, no difference in cell viability was 
seen between non-treated and butyrate treated cells (P>0.05, Figure 3.3B), which suggests 
that butyrate at these concentrations does not inhibit HT29 cell proliferation or viability. 
 
Figure 3.3: HT29 cell proliferation and viability following 24 hours of butyrate 
treatments. HT29 cells were treated with and without butyrate (0-8 mM). (A) Cell 
proliferation and (B) viability were assessed using the Trypan blue exclusion method. Each 
data set is representative of three independent experiment’s mean ± SEM. No significance 
(ns);P>0.05 when compared to untreated controls (one-way ANOVA with Dunnett’s multiple 






3.4 The effect of butyrate on B. fragilis viability 
ETBF and NTBF (1x108/mL suspended in 100 µL of B. fragilis growth medium) were grown 
anaerobically with and without the addition of butyrate (0-8 mM) for 24 hours in a 96-well 
plate. The absorbance of each sample was measured (A600) at 24 hours (Figure 3.4). The 
eight replicate wells containing bacteria were pooled, the pelleted bacteria were diluted in 
PBS (1x108/mL then 1/10,000,000 respectively) and inoculated onto Sheep Blood Agar 
plates (three technical repeats) to grow anaerobically for 48 hours. The colony forming units 
(CFUs) of each sample were enumerated and adjusted for the dilution factor to calculate the 
number of viable bacteria/mL (Figure 3.5). No difference in absorbance or CFUs was 
observed in the bacteria grown in butyrate compared to untreated controls (P>0.05), which 
suggests that butyrate at these concentrations does not inhibit B. fragilis growth or viability. 
 
Figure 3.4: B. fragilis growth in butyrate. (A) NTBF and (B) ETBF (1x108/mL) were grown 
with and without butyrate (0-8 mM) for 24 hours. Absorbance was measured using a Multiskan 
FC Microphotometer (A600nm). Each data set is representative of three independent 
experiments, mean ± SEM. ns; P>0.05 when compared to untreated controls (one-way 






Figure 3.5: B. fragilis viability following growth in butyrate. (A) NTBF and (B) ETBF 
(1x108/mL) grown with and without butyrate (0-8 mM) for 24 hours. Colony forming units 
(CFUs) were enumerated and adjusted for dilutions to estimate the number of bacterial/mL. 
Each data set is representative of three independent experiments, mean ± SEM. ns; P>0.05 







3.5 The effect of butyrate on CDH1 gene expression  
HT29 cells (5x104 cells/mL suspended in 1 mL of McCoy’s 5A growth medium) were grown 
for 48 hours in a 24-well plate prior to the addition of butyrate (0-8 mM) for a further 24 
hours. The expression of the CDH1 gene, which encodes for E-cadherin, was quantified using 
RT-qPCR. An average 3.30-fold increase (3.48 (P=0.0031), 3.45 (P=0.0293), 3.08-fold 
(P=0.0438) increase in 2mM, 4mM and 8mM respectively) in CDH1 gene expression was 
observed in butyrate-treated cells (Figure 3.6), which indicates that butyrate at these 
concentrations upregulates CDH1 gene expression in HT29 cells. This effect was not 
concentration dependent. Previous literature indicates that 5 mM of butyrate is often used as 
the standard treatment concentration to model epithelial cells responses (31, 91). 
Accordingly, this was selected as the concentration of butyrate used in subsequent 
experiments. 
 



































Figure 3.6: CDH1 expression in HT29 cells following 24 hours of butyrate treatment. 
HT29 cells were treated with and without butyrate (0-8 mM). CDH1 expression was quantified 
using RT-qPCR. Data from individual experiments (n=3) were normalised relative to gene 
expression (defined as fold increase =1) in cells cultured without butyrate, and are shown as 
fold change. Statistical analysis was performed on non-normalised by repeated measures of 
ANOVA in combination with Holm-Sidak’s post hoc test. Asterisks indicate significant 





3.6 The effect of butyrate on BFT-induced cell rounding 
HT29 cells (5x104 cells/mL suspended in 1 mL of McCoy’s 5A growth medium) were grown 
for 48 hours in a 24-well plate prior. The cells were infected with B. fragilis (MOI 500:1) 
and/or treated with or without butyrate for a further 24 hours (Figure 3.7). The relative 
amount of cell rounding in the cells treated with NTBF, butyrate, and NTBF in conjunction 
with butyrate did not appear to differ from the untreated cells (Figure 3.7A-D) However, the 
cells treated with 5 mM of butyrate, with or without the presence of B. fragilis, were 
observed to have an altered cellular morphology (Figure 3.7B, 3.7D, 3.7F). This change was 
defined by cell elongation and tapered protruding points, an observation that has not currently 
been mentioned in the literature. Approximately 50% of HT29 cells treated with ETBF at a 
MOI 500:1 showed evidence of cell rounding (Figure 3.7E). In contrast, cell rounding in the 






Figure 3.7: BFT-induced HT29 cell rounding in response to butyrate. The cells were either 
(A) untreated, treated with (B) 5 mM butyrate, (C) NTBF MOI 500:1, (D) NTBF MOI 500:1 
and 5 mM butyrate, (E) ETBF MOI 500:1, or (F) ETBF MOI 500:1 and 5 mM butyrate for 24 
hours. Bright-field microscopy was used to image cells at 10x magnification. Images are 








3.7 The effect of butyrate on BFT-induced loss of E-cadherin protein  
HT29 cells (1x104 cells/well suspended in 200 µL of McCoy’s 5A growth medium) were 
grown for 48 hours in a 96-well flat bottom plate prior to infection with B. fragilis (MOI 
500:1) and/or treated with or without butyrate for a further 24 hours. To visualise E-cadherin, 
fixed and permeabilised cells were immunostained to detect E-cadherin with Texas-red (red) 
and cell nuclei were stained using Hoechst (blue) (Figure 3.8).  
NTBF infected cells did not appear to differ in expression of E-cadherin on the plasma 
membrane (Figure 3.8A, 3.8C). Butyrate treated cells appeared to have a stronger expression 
of E-cadherin on the plasma membrane compared to the untreated cells (Figure 3.8A, 3.8D), 
suggestive of butyrate upregulating E-cadherin protein expression in HT29 cells. ETBF-
infected cells were associated with reduced E-cadherin (Figure 3.8E). However, when 
ETBF-infected cells were treated in conjunction with butyrate, E-cadherin at the cell surface 
appeared to be restored when compared to ETBF infection alone (Figure 3.8F). This 
suggests that 5 mM of butyrate may protect HT29 cells from toxin-mediated loss of E-





Figure 3.8: E-cadherin protein staining of infected HT29 cells in response to butyrate. 
Cells were either (A) untreated, (B) untreated with no primary antibody, treated with (C) NTBF 
500:1, (D) 5 mM butyrate, (E) ETBF 500:1 or (F) ETBF 500:1 and 5 mM butyrate. E-cadherin 
(red) and nuclei (blue) were detected using immunofluorescent microscopy. The 
ImageXpress® Pico Automated Cell Imaging System was used to visualise the cells at 40x 




3.8 The effects of butyrate on BFT-induced loss of CDH1  
HT29 cells were grown for 48 hours in a 24-well plate prior to infection with B. fragilis (MOI 
500:1) and/or treated with or without butyrate for a further 24 hours (Figure 3.9). There was 
no significant difference (P>0.05) in CDH1 expression between the untreated, NTBF and 
ETBF treated cells. There was a 3.32-fold increase (P=0.0158) in CDH1 expression in the 
NTBF infected cells treated with butyrate compared to cells solely treated with NTBF. As 
consistently observed (portrayed in section 3.5), cells treated with butyrate exhibited a 3.54-
fold increase (P=0.0133) in CDH1 expression compared to the untreated cells. There was a 
1.99-fold increase (P=0.0094) in CDH1 expression amongst the ETBF infected cells treated 
with butyrate compared to cells solely treated with ETBF. This indicates that 5 mM of 






Figure 3.9: CDH1 gene expression in response to butyrate in B. fragilis infected HT29 
cells. HT29 cells were untreated, treated with NTBF, ETBF, NTBF + butyrate, ETBF and 
butyrate, or butyrate alone. Butyrate (5 mM) and bacteria (MOI 500:1) were added for 24 hours. 
CDH1 expression was quantified using RT-qPCR. Data from individual experiments (n=3) 
were normalised relative to expression in untreated cells (defined as fold increase =1) and 
pooled data are shown as mean ± SEM. Statistical analysis of treated cells was performed on 
non-normalised data by repeated measures of ANOVA in combination with Tukey’s post hoc 
test. Asterisks linked by bars indicate significant differences between groups. One sample t-
tests were performed to determine whether fold increases in cells treated with NTBF, ETBF or 
butyrate alone were significantly different from 1 following correction for multiple 





The first objective of this chapter was to establish an optimal seeding cell density to yield 
80% confluency after 48 hours culture. HT29 cells seeded at a concentration of 1x105 
cells/mL were almost confluent after 48 hours, which would have limited the ability to 
visualise cell rounding as a marker of the toxigenic effect of BFT on HT29 cells. Likewise, 
cells seeded at 1x104 cells/mL were too sparse to observe the same affect (88). A seeding 
density of 5x104 cells/mL yielded ~80% confluency, which is reportedly the ideal density of 
cells to monitor exposure to the B. fragilis toxin (88), and was chosen as the seeding 
concentration for subsequent experiments. 
 
The next objective was to establish an optimal concentration (multiplicity of infection, MOI) 
of ETBF that resulted in ~50% of HT29 cell rounding following 24 hours of infection. Cell 
rounding was used as indicator of BFT-associated loss of intercellular E-cadherin (67, 73, 
92). ETBF added at MOIs of 10:1 to 300:1 were too low to achieve cell rounding greater than 
40%. ETBF added at a MOI 500:1 however, resulted in ~50% of the HT29 cells rounding. 
This was the MOI of ETBF to cells selected for subsequent experiments. 
 
The third objective was to establish a concentration of butyrate that did not significantly 
impact HT29 cell and/or B. fragilis growth and viability over a 24-hour period. Butyrate is 
present at 1-10 mM at physiological concentrations (29). Accordingly, HT29 cells and B. 
fragilis were treated and grown, respectively, in concentrations of butyrate that ranged from 
0-8 mM. Butyrate over this range of concentration had no observable effect on HT29 cell 
proliferation or viability over a 24-hour period. This does not coincide with the current 
literature which suggests that butyrate inhibits pro-oncogenes that facilitate cell proliferation 




treatment period was not sufficiently long enough to observe the suppression of cell 
proliferation and viability. A 24-hour treatment period was selected for these experiments 
because, in the absence of anaerobic conditions, B. fragilis viability declines over time 
(Keenan, unpublished observation). Additionally, there was no significant effect on B. 
fragilis growth and viability when treated with 2-8 mM of butyrate. However, 2-8 mM of 
butyrate significantly increased CDH1 expression in a non-concentration dependent manner. 
As previous literature has conventionally treated HT29 for 24 hours with 5 mM of butyrate, 
this was the concentration selected for subsequent experiments (31).  
 
The final objective was to investigate the effect of butyrate on HT29 cells, with and without 
the addition of B. fragilis. This was achieved by determining the effect of butyrate on HT29 
cell rounding, E-cadherin protein and CDH1 gene expression. 
 
Approximately 50% of HT29 cells treated with ETBF (MOI 500:1) demonstrated cell 
rounding after 24 hours. However, when the infected cells were concurrently treated with 5 
mM of butyrate, minimal cell rounding was observed that was comparable to the untreated or 
uninfected cells. This suggested that 5 mM of butyrate provides a level of protection against 
BFT-induced E-cadherin cleavage. To investigate this further, two approaches were taken. 
 
Firstly, immunofluorescent microscopy was used to visualise the effect that butyrate has on 
plasma membrane associated E-cadherin protein levels in B. fragilis infected HT29 cells. 
Cells treated with 5 mM of butyrate for 24 hours were observed to have increased E-cadherin 
staining at the cell surface compared to the untreated cells. In contrast, ETBF-infected cells 
appeared to have reduced staining of E-cadherin, as reported in the literature (73). However, 




was increased. This finding was consensus with the literature (59, 60). Although the exact 
cellular mechanism remains unknown, it is theorised that butyrate induces the translocation 
and suppression of nuclear transcription factors involved in the silencing of E-cadherin 
transcription (59). 
 
Secondly, this seemingly protective effect of butyrate in ETBF-infected cells was further 
investigated by quantifying levels of CDH1 gene expression. Treatment with 5 mM of 
butyrate for 24 hours was observed to increase CDH1 gene expression, as reported in the 
literature (31). In contrast, ETBF-infected cells were associated with a CDH1 gene 
expression comparable to the uninfected cells. However, CDH1 expression levels remained 
significantly increased in ETBF-infected cells in the presence of 5 mM butyrate. Collectively, 
these observations suggest that 5 mM of butyrate may offer a level of protection against BFT-
induced E-cadherin cleavage. 
 
In this chapter, butyrate was depicted to mitigate BFT-induced cleavage of E-cadherin in 
HT29 cells. Moreover, butyrate also upregulated E-cadherin at the level of gene expression 
(CDH1) in ETBF-infected cells. However, one limitation of a study that uses this non-
differentiated HT29 cell line is that the findings may lack biological relevance, given the 
presence of a mucus layer throughout the healthy colon. Accordingly, the next step of this 
project was to investigate the effect that butyrate has on mucus-producing HT29-MTX cells 





4 Results: HT29-MTX cells 
Background 
The effect of butyrate on the colonic epithelium has been explored in HT29 cells (31, 59, 60). 
However, one of the main limitations of the conventional HT29 cell culture model is that less 
than four percent of these cells in culture are representative of differentiated intestinal cell 
types: in particular, there is a lack of mucus secreting goblet cells (79). This is noteworthy 
considering that the colon is lined in vivo with a layer of mucus that increases in thickness 
from the proximal to the distal region (42, 45). HT29-MTX cells are HT29 cells that have 
been almost exclusively differentiated into mucus-secreting cells following exposure to 
methotrexate. Consequently, these cells represent a more physiologically relevant model of 
the colon (79).  
There is limited literature regarding the full effects of butyrate on the mucus layer (50-54). 
The most abundant class of intestinal mucin is mucin 2 (encoded by the MUC2 gene), which 
constitutes the majority of the colonic mucus layer (38, 43). In this chapter the HT29-MTX 
cell line was used to model the ETBF-infected colonic epithelium to test the hypothesis that 
the presence of mucin 2 may enhance the ability of butyrate to protect the cells from BFT-





1) Establish the effect that treatment with 5 mM of butyrate has on E-cadherin and mucus 
expression in HT29-MTX cells over time. 
2) Investigate E-cadherin and mucus expression in HT29-MTX cells with and without the 




4.1 The effect of butyrate on HT29-MTX cell phenotype 
HT29-MTX (5x104 cells/mL suspended in 1 mL of DMEM growth medium) cells were 
grown 24 hours prior to further culture, with and without the addition of 5 mM of butyrate for 
up to 10 days. The DMEM culture media was replaced every 2-3 days and the cells were 
imaged after 3, 7 and 10 days. 
Over the course of 3 to 10 days, both untreated and 5 mM butyrate treated cells developed 
small vesicle-like structures that grew in size and quantity over time. There was no apparent 
difference in cellular phenotype between the untreated and butyrate treated cells by day 3 
(Figure 4.1). By day 7, the vesicle-like structures were evident and appeared to be larger in 
the butyrate treated cells compared to the untreated cells (Figure 4.2). The structures did not 
appear to differ between days 7 and 10 in the butyrate treated cells. However, these structures 
in the untreated cells appeared to have increased in size by day 10, similar to the butyrate 
treated cells (Figure 4.3). The butyrate treated cells acquired a distinctive altered morphology 
that was defined by tapered protruding points, similar to the findings in the butyrate treated 
HT29 cells (Section 3.6, figure 3.7B), an observation that has not been detailed in the current 
literature. This may however, in part, reflect the observation that butyrate treated cells were 





Figure 4.1: HT29-MTX cell morphology after 3 days of treatment and growth with 
butyrate. The cells were either (A-B) untreated or treated with (C-D) 5 mM of butyrate. Bright-
field microscopy was used to image cells at 4x (A, C) and 10x (B, D) magnification. These 
images are representative of three independent experiments. Arrows indicate vesicle-like 
structures. 
 
Figure 4.2: HT29-MTX cell morphology after 7 days of treatment and growth with 
butyrate. The cells were either (E-F) untreated or treated with (G-H) 5 mM of butyrate. 
Bright-field microscopy was used to image cells at 4x (E, G) and 10x (F, H) magnification. 







Figure 4.3: HT29-MTX cell morphology after 10 days of treatment and growth with 
butyrate. The cells were either (I-J) untreated or treated with (K-L) 5 mM of butyrate. Bright-
field microscopy was used to image cells at 4x (I, K) and 10x (J, L) magnification. These 




4.2 The effect of butyrate on acidic mucus expression 
HT29-MTX cells (5x104 cells/mL suspended in 1 mL of DMEM growth medium) were 
grown with or without 5 mM of butyrate in a 24-well plate over 10 days. The cells were 
stained using Alcian blue, which dyes acidic mucins light blue (85). Cell nuclei were 
counterstained a deep blue-purple colour by haematoxylin (85). 
There was no apparent difference in Alcian blue staining between the untreated and butyrate 
treated cells at day 3 (Figure 4.4A-B). By day 7, Alcian blue staining of the vesicle-like 
structures (observed in section 4.1) confirmed that they were filled with acidic mucin. There 
was notably more mucin staining in the vesicles of the butyrate-treated cells compared to 




(Figure 4.4E and 4.4F). Moreover, the butyrate treated cells appeared to have increased in 
size compared to the untreated cells (Figure 4.4C-F). 
 
Figure 4.4: Acidic mucus staining in HT29-MTX cells in response to butyrate. The cells 
were either (A, C, E) untreated or treated with (B, D, F) 5 mM of butyrate. Bright-field 
microscopy was used to image cells at (A-B) 3, (C-D) 7 and (E-F) 10 days at 10x magnification. 
The Alcian blue staining protocol was used to dye acidic mucus light blue and counterstain cell 




4.3 Butyrate’s effect on CDH1 and MUC2 gene expression 
HT29-MTX cells (5x104 cells/mL suspended in 1 mL of DMEM growth medium) were 
grown with or without 5 mM of butyrate in a 24-well plate for up to 10 days. The expression 
of CDH1 (encodes for E-cadherin) and MUC2 (encodes for mucin 2) genes was quantified 
using RT-qPCR at three time points (days 3, 7 and 10).  
By day 3, butyrate induced a 2.8-fold increase (P=0.0053) in CDH1 gene expression 
compared to the untreated cells. CDH1 gene expression continued to increase in the butyrate 
treated cells and by day 10, there was a 7.32-fold difference (P=0.0009) between treated and 
untreated cells (Figure 4.5A). 
In contrast, butyrate treatment in HT29-MTX cells had the opposite effect on MUC2 gene 
expression. While no difference (P>0.05) in MUC2 expression was seen in treated and 
untreated cells at day 3 and 7, butyrate induced a 4.33-fold decrease (P=0.0110) in MUC2 
expression by day 10 (Figure 4.5B). 
 
Figure 4.5: CDH1 and MUC2 gene expression in HT29-MTX cells treated with butyrate. 
HT29-MTX cells were treated (▲) with and (●) without butyrate (0-8 mM). CDH1 and MUC2 
expression was quantified using RT-qPCR. Data from individual experiments (n=3) were 
normalised relative to gene expression (defined as fold increase =1) in cells cultured without 
butyrate, and are shown as fold change. Statistical analysis was performed on non-normalised 
data using repeated measures of analysis of variance in combination with Holm-Sidak’s post 
hoc test. Asterisks indicate significant difference between control and respective treatment 




4.4 Butyrate’s effect on E-cadherin and mucin 2 protein expression in B. 
fragilis-infected HT29-MTX cells 
HT29-MTX cells (1x104 cells/well suspended in 200 µL of DMEM growth medium) were 
grown for 10 days with or without 5 mM of butyrate in a 96-well flat bottom plate prior to 
infection with B. fragilis (MOI 500:1) and/or treatment with butyrate for a further 24 hours. 
Immunofluorescent microscopy was used to visualise E-cadherin with Texas-red (Red, figure 
4.6), and mucin 2 with FITC (green, figure 4.7). Cell nuclei were also stained with Hoechst 
(for image clarity, this staining is not published here). The omission of the primary antibody 
(Figure 4.6C, 4.6D, 4.7 C, 4.7D) ensured the specificity of the secondary antibody to the 
primary antibody only. 
There were no obvious qualitative differences in E-cadherin staining in untreated, ETBF and 
NTBF treated HT29-MITX cells (Figure 4.6A, 4.6E, 4.6G). The addition of butyrate to cells 
(with and without the addition of B, fragilis) made no apparent difference to the level of E-
cadherin staining in the different conditions (Figure 4.6B, 4.6F, 4.6H).  
Likewise, mucin 2 staining of untreated, ETBF and NTBF treated cells was remarkably 
similar across the cells (Figure 4.7A, 4.7E, 4.7G). There was no apparent difference between 
the cells treated with butyrate and the B. fragilis infected cells treated with butyrate (Figure 






Figure 4.6: E-cadherin protein staining of infected HT29-MTX cells in response to 
butyrate. HT29-MTX cells were (A&C) untreated, or treated (B&D) with butyrate, (E) ETBF, 
(F) ETBF and butyrate, (G) NTBF or (H) NTBF and butyrate. Butyrate (5 mM) and bacteria 
(MOI 500:1) were added for 24 hours. E-cadherin (Texas-Red) was stained using 
immunofluorescent microscopy. (C) and (D), primary antibody was omitted during staining. 
The ImageXpress® Pico Automated Cell Imaging System was used to visualise the cells at 40x 





Figure 4.7: Mucin 2 protein staining of infected HT29-MTX cells in response to butyrate. 
HT29-MTX cells were (A&C) untreated, or treated (B&D) with butyrate, (E) ETBF, (F) ETBF 
and butyrate, (G) NTBF or (H) NTBF and butyrate. Butyrate (5 mM) and bacteria (MOI 500:1) 
were added for 24 hours. Mucin 2 (FITC, green) was stained using immunofluorescent 
microscopy. (C) and (D), primary antibody was omitted during staining. The ImageXpress® 
Pico Automated Cell Imaging System was used to visualise the cells at 40x magnification. 





4.5 The effect of Butyrate on CDH1 and MUC2 gene expression in B. fragilis-
infected HT29-MTX cells 
HT29-MTX cells (5x104 cells/mL suspended in 1 mL of DMEM growth medium) were 
grown for 10 days with or without 5 mM of butyrate in a 24-well plate prior to infection with 
B. fragilis (MOI 500:1) and/or treatment with or without butyrate for a further 24 hours 
(Figure 4.8).  
There was no difference (P>0.05) in CDH1 expression between the untreated, NTBF and 
ETBF treated cells. However, the addition of 5 mM butyrate resulted in an increase (6.47-
fold, P<0.01) in CDH1 expression, even with the addition of NTBF (7.36-fold, P=0.0034) or 
ETBF (6.11-fold, P=0.0192, figure 4.8A). 
No difference in MUC2 expression was seen between untreated and the NTBF treated cells 
(Figure 4.8B). However, the addition of 5 mM butyrate to untreated and NTBF treated cells 
resulted in a 0.57 (P=0.0115) and 0.67-fold (P=0.0052) decrease in MUC2 expression, 
respectively. In contrast no significant difference in MUC2 expression was observed in ETBF 
infected cells with or without the addition of 5 mM butyrate. Moreover, a 0.67-fold decrease 
(P=0.0120) in MUC2 expression was seen in the ETBF-infected compared to NTBF infected 






Figure 4.8: CDH1 and MUC2 gene expression in B. fragilis infected HT29-MTX cells 
treated with butyrate. HT29-MTX cells were untreated, treated with NTBF, ETBF, NTBF + 
butyrate, ETBF and butyrate, or butyrate alone. Butyrate (5 mM) and bacteria (MOI 500:1) 
were added for 24 hours. CDH1 and MUC2 expression was quantified using RT-qPCR. Data 
from individual experiments (n=3) were normalised relative to expression in untreated cells 
(defined as fold increase =1) and pooled data are shown as mean ± SEM. Statistical analysis of 
treated cells was performed on non-normalised data by repeated measures ANOVA in 
combination with Tukey’s post hoc test. Asterisks linked by bars indicate significant 






The first objective of this chapter was to observe the effect that butyrate has on E-cadherin 
and mucus expression in HT29-MTX cells. This was achieved by observing the response of 
these cells to butyrate at 3, 7 and 10 days using bright-field microscopy, Alcian blue staining 
and RT-qPCR. 
 
On day 3, there was no apparent difference in the cell shape or numbers. By day 7, vesicle-
like structures in the butyrate treated cells appeared to be larger and more numerous than 
similar structures in the untreated cells. By day 10, the vesicle-like structures in the butyrate 
treated cells did not appear to differ from day 7. It is likely that these large vesicular 
structures were filled with mucin (based on the findings in section 4.2). If so, their large size 
might be attributable to compound exocytosis, in which the majority of mucin filled vesicles 
merge into one before fusing with the plasma membrane to facilitate secretion (93). By day 
10, the vesicle-like structures in the untreated cells appear to have increased in size 
comparable to the butyrate treated cells. This suggests that the butyrate cells reached 
compound exocytosis more rapidly than the untreated cells, indicating that butyrate drives 
mucus production.  
 
Mucus secreting cells synthesise mucins, which are stored in secretory granulae and are 
capable of occupying >75% of the cytoplasmic volume (39). These granulae structures are 
identified to contain mucins (39, 40). Using the Alcian blue staining protocol, the vesicle-like 
structures in section 4.1 were identified to be acidic mucin filled granulae (14, 40, 93). By 
day 7 it appeared that butyrate drives expression of mucin in these granulae compared to the 
untreated cells. This finding is more prevalent by day 10, where the Alcian blue is stained 




microscopy findings, these observations suggest that 5 mM of butyrate drives acidic mucin 
production and expression in HT29-MTX cells. This is in consensus with the finding of 
Hatayama et al. (51), where butyrate was associated with an increase in mucin 2 production 
in the mucus producing colorectal adenocarcinoma cell line LS174T. However, a study by 
Navabi et al. (54) observed that 5 mM of butyrate did not have an effect on mucin 2 
production in several colorectal adenocarcinoma cell lines, including LS174T and HT29-
MTX cells. This disparity in the literature may be best explained by Willemsen et al. (50), in 
which the effect that butyrate has on mucin 2 production is dependent on the cell line and 
culture conditions investigated. 
 
RT-qPCR analysis indicated that 5 mM of butyrate downregulated MUC2 gene expression in 
HT29-MTX cells by day 10. This is consensus with the limited literature which suggests that 
5-100 mM of butyrate reduces MUC2 (52, 53). However, at lower concentrations (1-2 mM), 
butyrate upregulates gene expression (51). It is suggested by Augenlicht et al. (53), that 
MUC2 is suppressed by butyrate’s function as a histone deacetylase inhibitor. This decrease 
in MUC2 expression contradicts the conclusion made in section 4.1 and 4.2, that butyrate 
drives acidic mucin production and expression in the mucin granulae. It is important to note 
however, that the occurrence of enlarged granulae or mucin expression is not necessarily an 
indication of mucin production, but potentially an accumulation as a result of defective 
secretion (93). Moreover, previous literature has often included HT29-MTX cells grown for 
up to 28 days post-confluency (39). In order to adapt to this project’s time frame, the 
maximum growth/treatment period was selected at 10 days. Further investigation is required 





In contrast, butyrate was observed to upregulate CDH1 expression. This indicates that 
butyrate significantly upregulates CDH1 in HT29 cells, irrespective of whether they are 
undifferentiated (HT29) or are phenotypically characterised as differentiated mucus secreting 
goblet cells (HT29-MTX). 
 
The second objective of this chapter was to investigate the effect of butyrate on HT29-MTX 
cells with and without the addition of B. fragilis over this time. This was achieved by 
observing the effect of butyrate on E-cadherin and mucin 2 protein levels as well as CDH1 
and MUC2 gene expression. To investigate this further, two approaches were taken. 
 
Firstly, immunofluorescent microscopy was used to visualise the effect that butyrate has on 
plasma membrane associated E-cadherin and mucin 2 protein levels in B. fragilis infected 
HT29-MTX cells. Because HT29-MTX cell confluency was severely affected by butyrate, 
the immunofluorescent staining of cell nuclei (Hoechst) was over-exposed, hence, was 
excluded in the published images. This disparity of cell density hindered the study’s ability to 
accurately compare E-cadherin and mucin 2 protein levels between untreated and butyrate 
treated cells. Hence, it could not be concluded if butyrate increases E-cadherin and/or mucin 
2 in uninfected HT29-MTX cells. 
 
There were no obvious qualitative differences in E-cadherin staining in untreated, ETBF and 
NTBF treated HT29-MTX cells. The addition of butyrate to cells (with and without the 
addition of B, fragilis) made no apparent difference to the level of E-cadherin staining in the 
different conditions. This was unanticipated as BFT is known to induce the indirect cleavage 




of BFT on E-cadherin expression in the HT29 and HT29-MTX cells raises the possibility that 
the mucus layer may offer a level of protection against BFT-induced E-cadherin cleavage. 
 
Mucin 2 staining of untreated, ETBF and NTBF treated cells was remarkably similar across 
the cells. This does not coincide with the findings by Dejea et al. (76) which detected that 
ETBF degrades colonic mucus. However, it is worthwhile to note that this study infected 
cells for a period longer than 24 hours (76). 
 
Secondly, this seemingly protective effect of butyrate in ETBF-infected cells was further 
investigated by quantifying levels of CDH1 and MUC2 gene expression. Butyrate was 
observed to increase CDH1 gene expression, as reported in the literature (31). This increase 
was observed regardless of B. fragilis infection. Moreover, CDH1 expression in ETBF-
infected cells was comparable to the untreated cells. In contrast, treatment with butyrate was 
observed to downregulate MUC2 gene expression, regardless of B. fragilis infection. 
Likewise, ETBF infection of the cells were associated with a reduction in MUC2 gene 
expression compared to the uninfected and NTBF-infected cells. This finding is supported by 
the observation that MUC2 expression decreased in neoplastic mice when treated with BFT2 
for 24 hours, although the exact cellular mechanism remains under speculation (77). These 
findings suggest that butyrate upregulates CDH1 and downregulates MUC2 expression in 
ETBF-infected HT29-MTX cells. Moreover, ETBF reduces MUC2 expression. 
 
In this chapter, butyrate was depicted to possibly reduce cell proliferation and/or viability. 
Additionally, butyrate may drive mucus production by increasing acidic mucin production 
and expression in mucin granulae of HT29-MTX cells. However, butyrate also reduced 




appeared to offer a level of protection against BFT-induced E-cadherin cleavage but further 






5.1 Summary of findings 
HT29 cells were used to model BFT-induced E-cadherin cleavage as conventionally reported 
in the literature (57, 73, 74, 88-90). Using bright-field microscopy, the concentration of 5x104 
cells/mL was selected as the optimal seeding density. These cells were observed to reach 
~80% confluency over 48 hours, which is the ideal confluency to assess toxin-induced cell 
morphology as the cells are neither too sparse nor overgrown (88).  
 
BFT-associated cell rounding of HT29 cells is used as a morphological indicator of toxin-
mediated E-cadherin protein cleavage (73, 95). It was established that an ETBF MOI of 500:1 
induced ~50% of HT29 cells to round 24 hours post-infection. This bacteria to cell ratio was 
selected for the subsequent experiments. 
 
Butyrate at concentrations of 2-8 mM were shown to not have a significant effect on HT29 
cell proliferation or viability over a 24-hour period. Likewise, 2-8 mM of butyrate was shown 
to have no significant effect on B. fragilis growth and viability. Additionally, RT-qPCR 
analysis indicated that 2-8 mM of butyrate significantly increased CDH1 expression in a non-
concentration dependent manner. Previous literature has conventionally treated HT29 cells 
for 24 hours with 5 mM of butyrate (8), and this concentration was selected for subsequent 
experiments.  
 
Cell rounding in ETBF-infected HT29 cells was observed to be minimised in the presence of 
5 mM of butyrate. Additionally, immunofluorescent microscopy revealed that butyrate 
increased E-cadherin protein levels in uninfected and ETBF-infected HT29 cells. This was 




upregulated CDH1 gene expression in uninfected and ETBF-infected HT29 cells. These 
findings suggest that 5 mM of butyrate upregulates E-cadherin protein and gene expression, 
which offers a level of protection against BFT-mediated cleavage of E-cadherin in these cells. 
 
Bright-field microscopy and Alcian blue staining appeared to indicate that exposure to 5 mM 
butyrate drives acidic mucin production and expression in HT29-MTC cells. However, 
concurrent RT-qPCR analysis found that this concentration of butyrate downregulated MUC2 
gene expression. This may be explained by the notion that the occurrence of enlarged 
granulae or mucin production is not necessarily an indication of mucin exocytosis, but may 
instead potentially indicate an accumulation of intracellular mucin as a result of defective 
secretion (96). In order to adapt to this project’s time frame, the maximum growth/treatment 
period of HT29-MTX cells during this project was 10 days. However, previous literature 
reports growing HT29-MTX cells for up to 28 days post-confluency (97). Further 
investigation is required to assess the effect that butyrate has on mucus production. However, 
butyrate upregulated CDH1 expression in HT29 cells, irrespective of whether the cells were 
undifferentiated (HT29) or differentiated and mucus secreting (HT29-MTX). 
 
The effect that butyrate was observed to have on E-cadherin and mucin 2 protein expression 
in HT29-MTX cells could not be concluded using immunofluorescent microscopy. This was 
due to the butyrate-related disparity in cell density after treatment. ETBF treatment of HT29-
MTX cells did not noticeably reduce E-cadherin staining in treated HT29-MTX cells, an 
observation that suggests the mucus layer may offer a level of protection against BFT-
binding to the cell-based receptor and associated E-cadherin cleavage. Likewise, there was no 
qualitative difference in mucin 2 staining between ETBF, NTBF-infected and untreated 




when the cells were co-cultured with butyrate and bacteria. This may reflect that the 24-hour 
treatment period was insufficient for the toxin to induce mucin degradation (76). However, 
within this time frame, ETBF was observed to reduce MUC2 expression.  
 
Overall, these findings suggest that butyrate acts to increase E-cadherin protein and gene 
expression, which protects against BFT-mediated E-cadherin loss in HT29 cells. 
Butyrate increases E-cadherin gene expression in ETBF-infected HT29-MTX cells. However, 
whether this translates into an upregulation of E-cadherin protein in these cells remains to be 
determined. Moreover, there is still uncertainty surrounding the effect that butyrate has on 




5.2 Future directions 
This study has demonstrated that butyrate acts to increase E-cadherin protein and gene 
expression that, in turn, may protect against BFT-mediated E-cadherin loss and therefore may 
help maintain epithelial homeostasis in the gut. While it is apparent that butyrate works at a 
cellular level, further investigation is required to investigate the effect of butyrate on E-
cadherin and/or mucus production in ETBF-infected HT29-MTX cells. 
Future work will aim to optimise the limitations of the butyrate-related cell density disparity 
in immunofluorescent microscopy of the HT29-MTX cells. Likewise, measures will be taken 
to optimise ETBF as a model to induce E-cadherin cleavage in HT29-MTX cells. Ideally, 
ImageJ software execution will be optimised to quantify protein fluorescence levels, 
providing a further objective measure to observations. Other quantitative techniques, such as 




Further investigation is needed to determine the effect butyrate has on mucus production. It is 
uncertain whether or not the mucin granulae was undergoing compound exocytosis, an 
indicator of mucous secretion, hence production between days 7 and 10. Future experiments 
may benefit from monitoring this time period to observe if exocytosis occurs. This study 
utilised MUC2 gene expression as an indicator of mucus production. Although mucin 2 is the 
most abundant constitute of intestinal mucins (38), further investigation on the other classes 
of secretory mucins should be considered.  
The current literature is limited in the precise mechanisms behind butyrate’s effect on mucus 
production. This study has provided insight into the effect of butyrate on E-cadherin and 
mucus production in relation to ETBF-infected HT29 and HT29-MTX cells. In order to 
further investigate butyrate as a potential chemo-preventative therapy against BFT-mediated 
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